Attenuation of behavioral abnormalities in autoimmune mice by chronic soluble interferon-gamma receptor treatment

Brain, Behavior, and Immunity
L M Schrott, L S Crnic

Abstract

NZB x NZW F1 hybrid (B/W) mice develop altered behavior in the elevated plus maze and novel object tasks between 6 and 12 weeks of age in parallel with lupus-like autoimmune disease. To confirm the relationship between disease progression and development of behavioral abnormalities, B/W and nonautoimmune NZW mice received chronic treatment with a soluble IFN gamma receptor (sIFN gamma R), a treatment known to retard autoimmune disease progression, or vehicle, beginning at 6 weeks of age. After 6 weeks of treatment, elevated plus maze and novel object testing revealed that although sIFN gamma R treated B/W mice still differed from NZW mice, chronic sIFN gamma R treatment significantly retarded the development of behavioral abnormalities in the B/W mice, while the NZW mice were not affected by this treatment. sIFN gamma R treated B/W mice were more active in both the plus maze and novel object tasks, and displayed less plus maze anxiety behavior and more exploratory activity in the novel object task compared to vehicle treated B/W mice. To clarify the role of acute action of the sIFN gamma R on the elevated IFN gamma levels of B/W mice, a second experiment examined the effects of a single injection of sIFN gamma R on B/W and NZW ...Continue Reading

References

Sep 1, 1978·Infection and Immunity·H HeremansP de Somer
Sep 1, 1992·Brain, Behavior, and Immunity·B SakićJ A Denburg
Dec 1, 1992·European Journal of Biochemistry·R GentzG Garotta
Oct 1, 1991·Annals of Internal Medicine·A D SteinbergA M Krieg
Jun 1, 1988·The American Journal of the Medical Sciences·A Schattner
Jan 1, 1988·Neuroscience and Biobehavioral Reviews·B L Hart
Jan 1, 1987·Psychopharmacology·R G Lister
Sep 1, 1987·The Journal of Experimental Medicine·C O JacobH O McDevitt
Sep 1, 1988·Brain, Behavior, and Immunity·S D DenburgJ A Denburg
Aug 1, 1969·Proceedings of the National Academy of Sciences of the United States of America·A D SteinbergN Talal
Jan 1, 1981·Immunological Reviews·A N Theofilopoulos, F J Dixon
Jul 1, 1982·Arthritis and Rheumatism·F J Dixon
May 1, 1984·Nihon rinsho. Japanese journal of clinical medicine·T Ofuji
Nov 1, 1982·Arthritis and Rheumatism·E M TanR J Winchester
Jan 1, 1994·Springer Seminars in Immunopathology·B S HandwergerC S Via
Sep 1, 1994·Pharmacology, Biochemistry, and Behavior·A P CruzF G Graeff
Nov 1, 1994·Physiology & Behavior·L M Schrott, L S Crnic
Nov 1, 1994·Neuropsychopharmacology : Official Publication of the American College of Neuropsychopharmacology·S C HeinrichsG F Koob
Sep 1, 1994·Physiology & Behavior·B SakićJ A Denburg
Dec 20, 1993·Behavioural Brain Research·S E File
Nov 1, 1993·Physiology & Behavior·B SakićJ A Denburg
Oct 29, 1993·Annals of the New York Academy of Sciences·A J Dunn
Mar 1, 1994·Clinical Immunology and Immunopathology·A Schattner
Apr 1, 1993·British Journal of Rheumatology·J G HanlyK Elkon
Feb 1, 1993·Seminars in Arthritis and Rheumatism·G L Iverson
Oct 1, 1995·Physiology & Behavior·B SakićJ A Denburg
Jun 1, 1996·Behavioral Neuroscience·L M Schrott, L S Crnic
Jan 1, 1996·Brain Research Bulletin·B SakićH Szechtman
May 1, 1997·Neuroscience and Biobehavioral Reviews·B SakićJ A Denburg
Jan 1, 1997·Brain Research Bulletin·B SakićJ A Denburg
Oct 23, 1997·Physiology & Behavior·N S WatersV H Denenberg

❮ Previous
Next ❯

Related Concepts

Related Feeds

Autoimmune Diseases

Autoimmune diseases occur as a result of an attack by the immune system on the body’s own tissues resulting in damage and dysfunction. There are different types of autoimmune diseases, in which there is a complex and unknown interaction between genetics and the environment. Discover the latest research on autoimmune diseases here.